<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Lung cancer is the leading cause of cancer-related mortality worldwide. Early diagnosis of lung cancer is hampered by the absence of specific symptoms and the lack of a widely recognised cost-effective screening programme. Acquisition of a tumour tissue sample for morphological and molecular genetic examination is of paramount importance for cancer diagnosis. We describe diagnostic challenges for early-stage lung cancer and their possible current solutions. Liquid biopsy is a relatively new technology that was developed for evaluation of tumour-related circulating genetic material. Recent achievements in data processing provide more opportunities for wider implementation of Next Generation Sequencing (NGS) in clinical practice. This article summarises available data on the current and future role of liquid biopsy in the management of lung cancer. We also present an ongoing Latvian lung cancer study that focuses on integration of liquid biopsy with comprehensive clinical data utilising advantages of information technologies.</p>
</abstract>

Lung cancer is the leading cause of cancer-related mortality worldwide. Early diagnosis of lung cancer is hampered by the absence of specific symptoms and the lack of a widely recognised cost-effective screening programme. Acquisition of a tumour tissue sample for morphological and molecular genetic examination is of paramount importance for cancer diagnosis. We describe diagnostic challenges for early-stage lung cancer and their possible current solutions. Liquid biopsy is a relatively new technology that was developed for evaluation of tumour-related circulating genetic material. Recent achievements in data processing provide more opportunities for wider implementation of Next Generation Sequencing (NGS) in clinical practice. This article summarises available data on the current and future role of liquid biopsy in the management of lung cancer. We also present an ongoing Latvian lung cancer study that focuses on integration of liquid biopsy with comprehensive clinical data utilising advantages of information technologies.

Liquid Biopsy — A Novel Diagnostic Tool for Management of Early-Stage Peripheral Lung Cancer

Rīga East University Hospital, Upeslejas, Ropaži Municipality

Faculty of Physics, Mathematics and Optometry

Innovation Centre of the University of Latvia LUMIC, University of Latvia

Medical board, Rīga East University Hospital

Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Lung cancer is the leading cause of cancer-related mortality worldwide. Early diagnosis of lung cancer is hampered by the absence of specific symptoms and the...

Liquid Biopsy — A Novel Diagnostic Tool for Management of Early-Stage Peripheral Lung Cancer

Published Online: Jul 23, 2022

Page range: 325 - 332

Received: Aug 31, 2021

Accepted: Jun 14, 2022

DOI: https://doi.org/10.2478/prolas-2022-0049

Keywords
pulmonary neoplasms, solitary pulmonary nodule, non-invasive diagnosis, molecular diagnostics

© 2022 Rihards Mikilps-Mikgelbs et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Liquid Biopsy — A Novel Diagnostic Tool for Management of Early-Stage Peripheral Lung Cancer

Published Online: Jul 23, 2022

Page range: 325 - 332

Received: Aug 31, 2021

Accepted: Jun 14, 2022

DOI: https://doi.org/10.2478/prolas-2022-0049

Keywordspulmonary neoplasms, solitary pulmonary nodule, non-invasive diagnosis, molecular diagnostics

© 2022 Rihards Mikilps-Mikgelbs et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Keywords
pulmonary neoplasms, solitary pulmonary nodule, non-invasive diagnosis, molecular diagnostics